Search Prime Grants

HT9425261E148

Project Grant

Overview

Grant Description
Therapeutic inactivation of the MYC oncogene as a treatment for triple negative breast cancer.
Awardee
The Leland Stanford Junior University
Funding Goals
BREAST CANCER RESEARCH PROGRAM. BREAKTHROUGH AWARD - FUNDING LEVEL 2 - PARTNERING PI OPTION.
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding / Funding Agency
Defense Health Agency (DHA) [DoD]
Place of Performance
Stanford, California 943052004 United States
Geographic Scope
Single Zip Code
Related Opportunity
DoD Breast Cancer, Breakthrough Award Levels 1 and 2 (HT942525BCRPBTA122)
The Leland Stanford Junior University was awarded Project Grant HT9425261E148 worth $604,151 from Defense Health Agency in May 2026 with work to be completed primarily in Stanford California United States. The grant has a duration of 3 years and was awarded through assistance program 12.420 Military Medical Research and Development. The Project Grant was awarded through grant opportunity DoD Breast Cancer, Breakthrough Award Levels 1 and 2.

Status
(Ongoing)

Last Modified 5/19/26

Period of Performance
5/15/26
Start Date
5/14/29
End Date
2.0% Complete

Funding Split
$604.2K
Federal Obligation
$0.0
Non-Federal Obligation
$604.2K
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to HT9425261E148

Additional Detail

Award ID FAIN
HT9425261E148
SAI Number
None
Award ID URI
None
Awardee Classifications
Private Institution Of Higher Education
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Other
Awarding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Funding Office
HT0989 CONG DIR MED RES PRGM / CDMRP - MM
Awardee UEI
HJD6G4D6TJY5
Awardee CAGE
1KN27
Performance District
CA-16
Senators
Dianne Feinstein
Alejandro Padilla
Modified: 5/19/26